Compatibility studies with pharmaceutical excipients for aripiprazole–heptakis (2,6-di-O-methyl)-β-cyclodextrin supramolecular adduct

被引:0
|
作者
Ionuț-Mihai Tănase
Laura Sbârcea
Adriana Ledeţi
Paul Barvinschi
Denisa Cîrcioban
Gabriela Vlase
Renata-Maria Văruţ
Ionuţ Ledeţi
机构
[1] Politehnica University of Timișoara,Faculty of Industrial Chemistry and Environmental Engineering
[2] “Victor Babeş” University of Medicine and Pharmacy,Department of Drug Analysis, Faculty of Pharmacy
[3] “Victor Babeş” University of Medicine and Pharmacy,Department of Analytical Chemistry, Faculty of Pharmacy
[4] West University of Timişoara,Faculty of Physics
[5] West University of Timisoara,Research Center for Thermal Analysis in Environmental Problems, Faculty of Chemistry
[6] University of Medicine and Pharmacy Craiova,Biology
[7] “Victor Babeş” University of Medicine and Pharmacy,Geography
关键词
Aripiprazole; Cyclodextrin; Inclusion complex; Thermal analysis; Excipient; Compatibility study;
D O I
暂无
中图分类号
学科分类号
摘要
Aripiprazole (ARP) is one of the newest antipsychotic drugs, exhibiting very low aqueous solubility and high lipophilicity. Considering the necessity of improvement of ARP physicochemical properties and its biopharmaceutical profile, cyclodextrin complexation of the drug substance was performed. As selected cyclodextrin, a functionalized β-cyclodextrin was used, namely heptakis(2,6-di-O-methyl)-β-cyclodextrin (DIMEB), and the supramolecular adduct ARP/DIMEB was prepared by kneading technique and characterized using thermoanalytical tools (TG—thermogravimetry/DTG—derivative thermogravimetry/HF—heat flow), powder X-ray diffractometry patterns (PXRD), universal-attenuated total reflectance Fourier transform infrared (UATR-FTIR) and UV (ultraviolet) spectroscopy and, as well, saturation solubility studies. Job’s method was used for the stoichiometry of APR/DIMEB inclusion complex determination, which was found to be 1:2. Molecular modeling studies were complementary realized as to get a view over the way that ARP is hosted inside the cyclodextrin. The compatibility between the inclusion complex and some common pharmaceutical excipients, namely starch, magnesium stearate, lactose monohydrate, microcrystalline cellulose and methylcellulose, has been evaluated by means of thermal methods of analysis (TG/DTG/HF), UATR-FTIR spectroscopy and PXRD pattern. The preformulation data regarding the compatibility of ARP/DIMEB complex with selected excipients suggested that under ambient conditions, chemical interactions are observed solely between ARP/DIMEB inclusion complex and magnesium stearate, as indicated by the UATR-FTIR spectroscopy. The incompatibility in the system ARP/DIMEB + MgS is also confirmed by the PXRD study, this second investigational technique revealing also the advanced amorphization of components during mixing of complex with starch, microcrystalline cellulose and methylcellulose, but without indicating interactions. Later on, under thermal stress, thermally induced interactions occur between the components in the systems containing magnesium stearate and methylcellulose, while starch, microcrystalline cellulose and lactose can be safely used as excipients in developing solid formulations containing ARP/DIMEB inclusion complex as active pharmaceutical ingredient.
引用
收藏
页码:1963 / 1976
页数:13
相关论文
共 50 条
  • [1] Compatibility studies with pharmaceutical excipients for aripiprazole-heptakis (2,6-di-O-methyl)-β-cyclodextrin supramolecular adduct
    Tanase, Ionut-Mihai
    Sbarcea, Laura
    Ledeti, Adriana
    Barvinschi, Paul
    Circioban, Denisa
    Vlase, Gabriela
    Varut, Renata-Maria
    Ledeti, Ionut
    JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY, 2020, 142 (05) : 1963 - 1976
  • [2] Inclusion phenomena of clove oil with α-, β-, γ- and heptakis (2,6-di-O-methyl)-β-cyclodextrin
    Song, L. X.
    Xu, P.
    Wang, H. M.
    Yang, Y.
    NATURAL PRODUCT RESEARCH, 2009, 23 (09) : 789 - 800
  • [3] HEPTAKIS(2,6-DI-O-METHYL)-BETA-CYCLODEXTRIN COMPLEXATION, WITH GLUTETHIMIDE
    ELGENDY, GA
    ELGENDY, MA
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1993, 39 (06) : 249 - 254
  • [4] Encapsulation of 6-hydroxyquinoline in heptakis(2,6-di-O-methyl)-β-cyclodextrin
    Lee, Young-Shin
    Park, Han Jung
    Jang, Du-Jeon
    BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2006, 27 (09) : 1450 - 1452
  • [5] Experimental and theoretical studies on the inclusion complexation of syringic acid with α-, β-, γ- and heptakis(2,6-di-O-methyl)-β-cyclodextrin
    Song, Le Xin
    Wang, Hai Ming
    Xu, Peng
    Yang, Yan
    Zhang, Zi Qiang
    CHEMICAL & PHARMACEUTICAL BULLETIN, 2008, 56 (04) : 468 - 474
  • [6] The Heptakis-(2,6-di-O-methyl)-β-cyclodextrin inclusion complex with acetic acid
    ER5128-CNRS, Centre Pharmaceutique, Université Paris-Sud, 92296 Chátenay-Malabry, France
    不详
    J. Incl. Phenom., 1 (1-12):
  • [7] The Heptakis-(2,6-di-O-methyl)-β-cyclodextrin Inclusion Complex with Acetic Acid
    M. Selkti
    A. Navaza
    F. Villain
    P. Charpin
    C. De Rango
    Journal of inclusion phenomena and molecular recognition in chemistry, 1997, 27 : 1 - 12
  • [8] Crystal structures and molecular dynamics studies of the inclusion compounds of β-citronellol in β-cyclodextrin, heptakis(2,6-di-O-methyl)-β-cyclodextrin and heptakis(2,3,6-tri-O-methyl)-β-cyclodextrin
    Fourtaka, Katerina
    Christoforides, Elias
    Mentzafos, Dimitris
    Bethanis, Kostas
    JOURNAL OF MOLECULAR STRUCTURE, 2018, 1161 : 1 - 8
  • [9] Electrochemical studies on the complexation of hydrophilic viologens with beta-cyclodextrin and heptakis(2,6-di-O-methyl)-beta-cyclodextrin.
    Kaifer, AE
    Mirzoian, A
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 76 - ANYL
  • [10] Formation, characterization and pH dependence of rifampicin: heptakis( 2,6-di-O-methyl)-β-cyclodextrin complexes
    Angiolini, Lorenzo
    Agnes, Marco
    Cohen, Boiko
    Yannakopoulou, Konstantina
    Douhal, Abderrazzak
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2017, 531 (02) : 668 - 675